NDAORALTABLET, EXTENDED RELEASE
Approved
Apr 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
KLOR-CON (potassium chloride) by Ascentage Pharma is tissues. First approved in 1986.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KLOR-CON is an oral extended-release tablet formulation of potassium chloride, a mineral supplement used to treat or prevent hypokalemia (low potassium levels). Potassium is essential for nerve impulse transmission, muscle contraction, and maintenance of normal cardiac and renal function, with the drug restoring serum potassium to the normal range of 3.5–5 mEq/L.
$11MPart D
LOE ApproachingLow spending ($11M, Part D) and modest claim volume (49K) indicate a mature, legacy product with declining commercial resources and smaller team footprint.
Mechanism of Action
tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function. The intracellular…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KLOR-CON offers limited career growth opportunity given its LOE-approaching status, minimal linked job postings (0), and small commercial footprint ($11M spending). Roles on this product are typically in cost management, generics optimization, and maintenance of declining market share rather than innovation or expansion.
Worked on KLOR-CON at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.